...
机译:对PD-1封锁的免疫介导的不良事件进行治疗的康威属
Department of Hematology Oncology Leo Jenkins Cancer Center at East Carolina University;
Department of Hematology Oncology Leo Jenkins Cancer Center at East Carolina University;
Department of Hematology Oncology Leo Jenkins Cancer Center at East Carolina University;
Department of Hematology Oncology Leo Jenkins Cancer Center at East Carolina University;
Department of Hematology Oncology Leo Jenkins Cancer Center at East Carolina University;
Department of Hematology Oncology Leo Jenkins Cancer Center at East Carolina University;
Department of Hematology Oncology Leo Jenkins Cancer Center at East Carolina University;
Department of Hematology Oncology Leo Jenkins Cancer Center at East Carolina University;
Department of Hematology Oncology Leo Jenkins Cancer Center at East Carolina University;
Department of Hematology Oncology Leo Jenkins Cancer Center at East Carolina University;
C-reactive protein; Immune checkpoint inhibitors; Immune mediated adverse events; nivolumab; tocilizumab;
机译:对PD-1封锁的免疫介导的不良事件进行治疗的康威属
机译:晚期黑色素瘤患者PD-1阻断与nivolumab合并后的严重结肠炎:Th1优势免疫反应在免疫相关不良事件中的潜在作用:两例病例报告
机译:Ipilimumab CTLA-4阻断疗法相关的免疫介导不良事件:基本机制和临床管理
机译:多次服用灭活的流感疫苗,以提供快速的天然免疫系统介导的和随后的长期适应性免疫力,以应对流感和第二次肺炎球菌感染
机译:在需要神经肌肉阻滞的手术患者中,罗库溴铵或维库溴铵是否增加了术后不良呼吸事件的发生率?
机译:在晚期黑素瘤患者中PD-1与尼古拉单抗被阻断后的严重结肠炎:Th1优势免疫反应在免疫相关不良事件中的潜在作用:两例病例报告
机译:POS1341对免疫检查点抑制剂的免疫相关不良事件进行治疗:案例系列